These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16086916)
1. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Becker RC Am Heart J; 2005 Aug; 150(2):189-92. PubMed ID: 16086916 [No Abstract] [Full Text] [Related]
2. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Am J Heart 2005;150:189-92). Aggarwal A Am Heart J; 2006 May; 151(5):e2. PubMed ID: 16644303 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049 [TBL] [Abstract][Full Text] [Related]
4. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ; J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793 [TBL] [Abstract][Full Text] [Related]
5. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. Mahaffey KW; Ferguson JJ Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952 [TBL] [Abstract][Full Text] [Related]
6. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. Petersen JL; Mahaffey KW; Becker RC; Goodman SG; Kleiman NS; Marian AJ; Stone GW; Lansky AJ; Lincoff AM; Hazen SL; Nessel CC; Toro-Figueroa L; Tate L; Reist CJ; Cohen M; Califf RM; Ferguson JJ; Am Heart J; 2004 Aug; 148(2):269-76. PubMed ID: 15308996 [TBL] [Abstract][Full Text] [Related]
7. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. Topol EJ Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950 [No Abstract] [Full Text] [Related]
8. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953 [TBL] [Abstract][Full Text] [Related]
9. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657 [TBL] [Abstract][Full Text] [Related]
10. [Low-molecular-weight heparin - enoxaparin (clexane) in the prevention of thromboembolic complications in surgical patients]. Zabolotskikh IB; Sin'kov SV; Klevko VA Anesteziol Reanimatol; 2001; (2):70-5. PubMed ID: 11494909 [No Abstract] [Full Text] [Related]
11. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E; Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078 [TBL] [Abstract][Full Text] [Related]
12. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Tricoci P; Lokhnygina Y; Berdan LG; Steinhubl SR; Gulba DC; White HD; Kleiman NS; Aylward PE; Langer A; Califf RM; Ferguson JJ; Antman EM; Newby LK; Harrington RA; Goodman SG; Mahaffey KW Circulation; 2007 Dec; 116(23):2669-77. PubMed ID: 18025532 [TBL] [Abstract][Full Text] [Related]
13. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426 [TBL] [Abstract][Full Text] [Related]
14. Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. DeCarolis DD N Engl J Med; 2006 Jun; 354(26):2830; author reply 2831-2. PubMed ID: 16807424 [No Abstract] [Full Text] [Related]
15. Clarifying the conundrum of conjunctive anticoagulation and coronary thrombolysis. Sobel BE Coron Artery Dis; 1995 Jan; 6(1):83-6. PubMed ID: 7767507 [No Abstract] [Full Text] [Related]
16. Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter? Brener SJ JACC Cardiovasc Interv; 2009 Nov; 2(11):1092-4. PubMed ID: 19926049 [No Abstract] [Full Text] [Related]